The Food and Drug Administration has approved the first factor XIa inhibitor intended to help prevent stroke, opening a new chapter in anticoagulant therapy that drugmakers have pursued for years in hopes of reducing bleeding complications tied to older blood thinners, according to recent reporting. The approval arrived alongside two other FDA decisions this week covering a rare joint tumor and a common inflammatory joint disease, underscoring an active stretch for the agency's drug review pipeline.

New Anticoagulant Class Targets Stroke Prevention

The FDA's approval of the first factor XIa inhibitor marks a notable shift in how doctors may approach stroke prevention, particularly for patients at risk of blood clots. Factor XIa inhibitors work differently than the anticoagulants most widely prescribed today, including warfarin and the newer factor Xa inhibitors, by targeting an earlier step in the body's clotting cascade. Researchers have pursued this mechanism because it theoretically allows the drug to reduce clot formation without raising bleeding risk as much as existing therapies.

Bleeding is the central trade-off physicians weigh when prescribing any anticoagulant, since the same mechanism that prevents dangerous clots can also impair the body's ability to stop bleeding elsewhere. Stroke prevention drugs are typically prescribed long-term to patients with conditions such as atrial fibrillation, making the bleeding-risk profile a major factor in both clinical decision-making and drug pricing negotiations with insurers. A therapy that can match or improve on stroke-prevention efficacy while lowering bleeding complications would carry significant value for health systems managing long-term anticoagulation costs.

The approval adds to a string of FDA decisions this fall, following moves such as the agency's recent clearance of Hibsago for chronic hepatitis B, which also introduced a new drug mechanism to an established treatment category.

Merck KGaA's Pimjetmi Approved for Rare Joint Tumor

The FDA has approved Pimjetmi, a drug from Merck KGaA, for tenosynovial giant cell tumor, or TGCT, a rare growth that develops in the lining of joints and tendons. TGCT is not cancerous but can cause pain, swelling and reduced joint mobility, and it has historically been managed primarily through surgery, which carries a meaningful risk of recurrence.

Because TGCT is uncommon, treatment options have been limited, and patients facing repeat surgeries often deal with ongoing disruption to daily life and mobility. An approved systemic therapy gives physicians a non-surgical option to offer patients, particularly those whose tumors are difficult to fully remove or who face a high chance of the tumor returning. As with many rare-disease approvals, pricing and insurance coverage will likely shape how quickly the drug reaches patients, a dynamic regulators have been trying to address more broadly through initiatives like the FDA's rare disease framework opened for public comment last month.

Tildrakizumab Becomes Third IL-23 Inhibitor for Psoriatic Arthritis

Tildrakizumab has been approved by the FDA for treating psoriatic arthritis in adults, becoming the third IL-23 inhibitor cleared for this indication. Psoriatic arthritis is a chronic inflammatory condition that affects some people with psoriasis, causing joint pain, stiffness and swelling that can worsen over time without treatment.

IL-23 inhibitors work by blocking a protein that drives inflammation in the immune system, and the drug class has already reshaped treatment for plaque psoriasis in recent years. Tildrakizumab's expanded approval gives rheumatologists and dermatologists another option within a drug class that has shown an ability to control both skin and joint symptoms, though as with other biologic therapies, cost and insurance coverage remain central considerations for patients weighing treatment choices.